VBL Therapeutics Reports Full Phase 2 Data From Clinical Trial Of VB-111 In Recurrent Glioblastoma (rGBM) At The 2015 Conference, Meeting The Primary Endpoint Of Statistically-Significant Increase In Overall Survival

Press/Media: Press / Media

PeriodSep 28 2015

Media coverage

1

Media coverage

  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial Of VB-111 In Recurrent Glioblastoma (rGBM) At The 2015 Conference, Meeting The Primary Endpoint Of Statistically-Significant Increase In Overall Survival
    Media name/outletBioSpace
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner